Protocol outlines DNA extraction from blood, quality control, SNP, and APOE genotyping. Adapted from PRoBaND SNP Genotyping and ApoE Genotyping Protocol by Malek et al. for Parkinson's Disease study.
Parkinson's disease progression varies among patients. Predicting progression accurately is crucial for clinical trial selection. Blood biomarkers like serum NfL, along with genetic factors (GBA, APOE) can enhance prediction beyond age and phenotype.
This protocol uses a classical ELISA experimental design with sensitive electrochemical detection to provide measure of 𝜶-synuclein concentration in the conditioned media of cultured iPSC-derived human cells.
